Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Gambro is a global medical technology company that specializes in developing, manufacturing, and supplying products and therapies for kidney and liver dialysis, as well as other extracorporeal therapies for chronic and acute patients. Founded in Sweden in 1964, the company became a pioneer in the field of hemodialysis with the introduction of the first disposable artificial kidney. Its product portfolio includes advanced hemodialysis machines, dialyzers, and continuous renal replacement therapy (CRRT) systems used in intensive care units. In 2013, Gambro was acquired by Baxter International, integrating its extensive renal care expertise into Baxter's global operations. Today, its legacy continues through the widely used Prismaflex and Artis systems, which remain critical in treating patients with end-stage renal disease and acute kidney injury.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Gambro.